Zepbound vs Wegovy: Which Weight Loss Medication Works Better?

If you're exploring prescription weight loss medications, you've likely come across two names that keep coming up: Zepbound and Wegovy. Both have made headlines for delivering results that diet and exercise alone often can't achieve, but choosing between them isn't always straightforward. Understanding how they differ, what results you can realistically expect, and which might work better for your body can help you make an informed decision with your healthcare provider.

What Are Zepbound and Wegovy?

Both Zepbound and Wegovy belong to a class of medications that mimic hormones your body naturally produces to regulate appetite and blood sugar. They're administered as once-weekly injections and have been approved by the FDA specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition.

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the glucagon-like peptide-1 hormone. It was approved by the FDA for weight loss in June 2021 and has been extensively studied in clinical trials.

Zepbound contains tirzepatide, which is actually a dual-action medication. It activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism earned it FDA approval for weight management in November 2023.

How They Work in Your Body

Both medications work primarily by reducing your appetite and helping you feel fuller longer, but they accomplish this through slightly different pathways.

Wegovy's semaglutide acts on GLP-1 receptors in your brain to decrease hunger signals and slow how quickly food leaves your stomach. This combination helps you eat less without the constant battle against hunger that makes traditional dieting so difficult.

Zepbound takes this a step further with its dual action. By activating both GLP-1 and GIP receptors, tirzepatide may offer enhanced effects on appetite suppression, insulin sensitivity, and fat metabolism. Some researchers believe this dual mechanism explains why Zepbound tends to produce slightly more weight loss in head-to-head comparisons.

Weight Loss Results: What the Research Shows

When it comes to effectiveness, both medications deliver impressive results that go well beyond what lifestyle changes alone typically achieve.

In clinical trials, people taking Wegovy lost an average of 15-17% of their body weight over 68 weeks. For someone weighing 230 pounds, that translates to roughly 35-40 pounds.

Zepbound's clinical trials showed even more dramatic results, with participants losing an average of 18-22% of their body weight over 72 weeks, depending on the dose. That same 230-pound person might lose 40-50 pounds.

It's important to remember these are averages. Individual results vary significantly based on starting weight, adherence to the medication, lifestyle factors, and metabolic differences. Some people respond exceptionally well to one medication while others may find better results with the alternative.

Gender Differences in Response

While both medications work effectively regardless of gender, some research suggests women may experience slightly more nausea initially, particularly during dose escalation. Men tend to have higher starting weights on average, which can mean more absolute pounds lost, though percentage of body weight lost is typically similar. Hormonal factors, including menstrual cycles and menopause status, may influence how women experience side effects but don't significantly impact overall effectiveness.

Side Effects and Tolerability

Both medications share similar side effect profiles, with gastrointestinal issues being the most common complaint.

The most frequently reported side effects include nausea, diarrhea, constipation, vomiting, and abdominal discomfort. These effects are typically most pronounced when starting the medication or increasing the dose, and they often improve over time as your body adjusts.

Some people find Zepbound slightly harder to tolerate initially due to its dual mechanism, while others report fewer side effects compared to Wegovy. There's no reliable way to predict which you'll tolerate better without trying.

Both medications carry similar warnings about potential risks, including thyroid tumors (seen in animal studies), pancreatitis, gallbladder problems, and kidney issues. Your healthcare provider should review your complete medical history before prescribing either medication.

Dosing and Administration

Both Zepbound and Wegovy are self-administered once weekly via subcutaneous injection, typically in your abdomen, thigh, or upper arm.

Wegovy starts at 0.25 mg weekly and gradually increases over 16-20 weeks to a maintenance dose of 2.4 mg weekly. This slow escalation helps your body adjust and minimizes side effects.

Zepbound also follows a gradual increase schedule, starting at 2.5 mg weekly and potentially increasing to 5 mg, 10 mg, or a maximum of 15 mg weekly, depending on your response and tolerance.

Cost and Insurance Coverage

This is where things get complicated and often frustrating for patients.

Without insurance, both medications are expensive. Wegovy typically costs around $1,300-$1,400 per month, while Zepbound runs approximately $1,000-$1,100 monthly at list price.

Insurance coverage varies dramatically. Some plans cover one but not the other, some cover neither, and coverage often depends on whether you have specific obesity-related health conditions. Prior authorization requirements can add weeks to the process.

Many patients find that compounded versions of semaglutide and tirzepatide offer a more affordable alternative, often at a fraction of the brand-name cost.

Which One Is Right for You?

There's no universal answer to whether Zepbound or Wegovy works better because individual responses vary significantly.

Zepbound's clinical data shows slightly greater average weight loss, which may make it the preferred choice if maximum weight loss is your primary goal and you can access it affordably. However, Wegovy has been available longer with more real-world evidence and may be easier to obtain through insurance or pharmacies.

Your decision should involve a thorough conversation with your healthcare provider about your medical history, weight loss goals, other medications you're taking, and practical considerations like cost and availability.

At Ozari Health, we offer compounded Semaglutide and Tirzepatide as low as $99/month, prescribed by licensed physicians and shipped to your door. Learn more at ozarihealth.com.

---

Medically Reviewed — Ozari Clinical Content Team (OCCT). Health writers and wellness professionals specializing in GLP-1 therapy, metabolic health, and weight loss medicine. Content reviewed in accordance with Ozari's Editorial Standards. Last reviewed: April 25, 2026.

This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.

Last reviewed: April 25, 2026